Lixte Biotechnology Holdings Files 8-K on Shareholder Vote Matters
Ticker: LIXT · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1335105
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: LIXT
TL;DR
LIXT filed an 8-K for a shareholder vote on Dec 19th.
AI Summary
Lixte Biotechnology Holdings, Inc. filed an 8-K on December 20, 2024, reporting on a submission of matters to a vote of security holders that occurred on December 19, 2024. The company, incorporated in Delaware, is involved in the Pharmaceutical Preparations industry.
Why It Matters
This filing indicates that Lixte Biotechnology Holdings, Inc. is engaging in corporate actions requiring shareholder approval, which could impact the company's future direction and governance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant
- December 19, 2024 (date) — Date of earliest event reported
- December 20, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 20-2903526 (identifier) — I.R.S. Employer Identification Number
FAQ
What specific matters were submitted for a vote of security holders?
The filing does not specify the exact matters submitted for a vote of security holders, only that such a submission occurred on December 19, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 19, 2024.
What is the primary business of Lixte Biotechnology Holdings, Inc. according to the filing?
According to the filing, Lixte Biotechnology Holdings, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
In which state is Lixte Biotechnology Holdings, Inc. incorporated?
Lixte Biotechnology Holdings, Inc. is incorporated in Delaware.
What is the filing date of this Current Report on Form 8-K?
This Current Report on Form 8-K was filed on December 20, 2024.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-12-20 16:05:24
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LIXT The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 48KB
- 0001493152-24-051050.txt ( ) — 266KB
- lixt-20241219.xsd (EX-101.SCH) — 4KB
- lixt-20241219_def.xml (EX-101.DEF) — 29KB
- lixt-20241219_lab.xml (EX-101.LAB) — 36KB
- lixt-20241219_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On December 19, 2024, the Company held its Annual Meeting . The matters voted upon were: Proposal 1: The election of five director nominees to the Company's Board of Directors to serve for a one-year term expiring at the 2025 annual meeting of stockholders. Proposal 2: To ratify the appointment of Weinberg & Company, P.A. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Proposal 3: To approve, on an advisory basis, the compensation of the Company's named executive officers. The results of the voting were as follows: Proposal 1 (election of directors): Each of the director nominees to the Company's Board of Directors was elected as follows: Nominee Votes For Votes Withheld Broker Non-Votes Dr. Stephen Forman 653,305 80,078 670,623 Dr. Yun Yen 691,844 41,615 670,547 Regina Brown 691,346 42,113 670,547 Dr. Ren Bernards 691,863 41,596 670,547 Bas van der Baan 678,222 55,161 670,623 Proposal 2 (appointment of accounting firm): Votes For Votes Against Abstain Broker Non-Votes 1,329,980 56,472 17,554 0 Proposal 3 (compensation of officers): Votes For Votes Against Abstain Broker Non-Votes 672,202 40,248 21,009 670,547 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 20, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan Chief Executive Officer 3